{"id":90836,"date":"2024-06-26T12:27:55","date_gmt":"2024-06-26T17:27:55","guid":{"rendered":"https:\/\/pulmonx.com\/patient-selection\/"},"modified":"2026-04-15T12:41:12","modified_gmt":"2026-04-15T17:41:12","slug":"patient-selection","status":"publish","type":"page","link":"https:\/\/pulmonx.com\/uk-en\/patient-selection\/","title":{"rendered":"Patient Selection"},"content":{"rendered":"\n
\n
\n
\n
\n <\/div>\n <\/div>\n <\/div>\n
\n
\n
\n
\n
\n \n
\n
\n

Patient Selection for the Zephyr\u00ae<\/sup> Valve
\n<\/b><\/h1>\n <\/div>\n<\/div>\n <\/div>\n <\/div>\n
\n
\n \n
\n
\n

A Proven Treatment for Breathlessness From Severe COPD\/Emphysema<\/h2> <\/div>\n<\/div>\n\n
\n
\n

A Proven Treatment for Breathlessness
From Severe COPD\/Emphysema<\/h2> <\/div>\n<\/div>\n\n
\n
\n

The Zephyr Valve is a clinically-proven bronchoscopic treatment for patients with severe COPD\/emphysema who suffer from shortness of breath despite optimized medical therapy.<\/p>\n

Appropriate patient selection is critical to the success of Zephyr Valve treatment. Over time, clinical trial data have helped define the successful patient profile.1-4,6,7<\/sup><\/a> The Zephyr Valve is the first endobronchial valve to receive approval from the FDA for patients with either heterogeneous or homogeneous emphysema and can be used to treat the upper and lower lobes of either lung.<\/p>\n

Patient Eligibility for Zephyr Valve Treatment<\/h2>\n

If shortness of breath is not controlled with medical management, patients may qualify for Zephyr Valve Treatment.<\/p> <\/div>\n<\/div>\n <\/div>\n <\/div>\n <\/div>\n <\/div>\n <\/div>\n

\n
\n
\n \n
\n
\n

Medical History<\/h4>\n